The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity ...

Shares of Novo Nordisk, the Danish maker of Ozempic and Wegovy, which had long led the weight-control drug sales, fell after analysts at brokerage Deutsche Bank said a $9 billion attempt to wrest ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, seeking to block Novo's rival takeover bid unveiled Thursday.

Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...